September 2015 | Oncology Business News

Alternative Payment Plan Works Only With Large Patient Cohorts

September 11, 2015

The experiment with bundled care in oncology is moving forward despite mixed results and lingering concerns about the administrative difficulty of implementation, potential care compromises, and whether innovation can thrive under fixed payments.

Alternative Payment Plan Focuses on Relevant Clinical Outcomes

September 08, 2015

As long as bundles are tied to a desired clinical outcome of relevance to the patients, we can truly move toward value-based medicine and enable the Goldilocks formula of delivery: just the right amount of care, not too much, and not too little-every time.

Necitumumab Assigned "Low Value" in Lung Cancer by Emory and Georgia Tech

August 28, 2015

New drug candidate necitumumab, which is being reviewed by the FDA as a treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, received a low cost-effectiveness evaluation in a study published in JAMA Oncology.

NCCN Strives to Control Cost of Cancer Drugs With New Evaluation Framework

August 25, 2015

As cancer drugs soar in price, the National Comprehensive Cancer Network is introducing cost as a measure of the overall value of a therapy, following the trail of ASCO and a doctor from Memorial Sloan Kettering Cancer Center in attempting to put a lid on drug inflation.